A detailed history of Paragon Associates & Paragon Associates Ii Joint Venture transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Paragon Associates & Paragon Associates Ii Joint Venture holds 482,614 shares of DMAC stock, worth $2.33 Million. This represents 3.74% of its overall portfolio holdings.

Number of Shares
482,614
Previous 482,614 -0.0%
Holding current value
$2.33 Million
Previous $1.42 Million 42.09%
% of portfolio
3.74%
Previous 3.48%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.16 - $3.66 $37,553 - $63,632
-17,386 Reduced 3.48%
482,614 $1.42 Million
Q4 2023

Feb 14, 2024

BUY
$2.05 - $2.99 $61,499 - $89,700
30,000 Added 6.38%
500,000 $1.42 Million
Q3 2023

Nov 14, 2023

BUY
$2.56 - $4.4 $371,200 - $638,000
145,000 Added 44.62%
470,000 $1.21 Million
Q2 2023

Aug 14, 2023

BUY
$1.53 - $4.4 $497,250 - $1.43 Million
325,000 New
325,000 $1.4 Million

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $128M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Paragon Associates & Paragon Associates Ii Joint Venture Portfolio

Follow Paragon Associates & Paragon Associates Ii Joint Venture and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paragon Associates & Paragon Associates Ii Joint Venture, based on Form 13F filings with the SEC.

News

Stay updated on Paragon Associates & Paragon Associates Ii Joint Venture with notifications on news.